Biogen Inc. (NASDAQ:BIIB) Shares Sold by Banco Bilbao Vizcaya Argentaria S.A.

Banco Bilbao Vizcaya Argentaria S.A. lowered its holdings in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 1.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 127,282 shares of the biotechnology company's stock after selling 2,418 shares during the period. Banco Bilbao Vizcaya Argentaria S.A. owned 0.09% of Biogen worth $19,445,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Inspire Trust Co. N.A. increased its position in Biogen by 58.5% in the 3rd quarter. Inspire Trust Co. N.A. now owns 10,900 shares of the biotechnology company's stock valued at $2,113,000 after acquiring an additional 4,025 shares during the period. Assenagon Asset Management S.A. lifted its holdings in shares of Biogen by 0.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 43,460 shares of the biotechnology company's stock worth $6,646,000 after purchasing an additional 111 shares during the period. Amundi increased its stake in Biogen by 35.6% in the 4th quarter. Amundi now owns 1,216,990 shares of the biotechnology company's stock valued at $183,461,000 after buying an additional 319,478 shares during the period. Centre Asset Management LLC raised its position in Biogen by 7.7% during the 4th quarter. Centre Asset Management LLC now owns 51,530 shares of the biotechnology company's stock worth $7,880,000 after buying an additional 3,698 shares during the last quarter. Finally, Integrated Quantitative Investments LLC acquired a new stake in shares of Biogen in the 4th quarter worth $407,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Biogen Stock Up 0.8 %

NASDAQ BIIB traded up $1.00 during trading hours on Tuesday, reaching $120.12. 426,344 shares of the company traded hands, compared to its average volume of 1,346,636. The stock has a market capitalization of $17.58 billion, a PE ratio of 10.73, a PEG ratio of 1.51 and a beta of 0.06. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.27. Biogen Inc. has a 12 month low of $110.04 and a 12 month high of $238.00. The company has a 50 day moving average of $132.12 and a two-hundred day moving average of $148.38.

Biogen (NASDAQ:BIIB - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported $3.44 earnings per share for the quarter, beating the consensus estimate of $3.43 by $0.01. Biogen had a return on equity of 14.98% and a net margin of 16.87%. As a group, equities analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Analysts Set New Price Targets

A number of brokerages recently commented on BIIB. Needham & Company LLC restated a "hold" rating on shares of Biogen in a research report on Friday. Argus lowered Biogen from a "buy" rating to a "hold" rating in a report on Friday, April 4th. Wells Fargo & Company lowered their target price on shares of Biogen from $165.00 to $140.00 and set an "equal weight" rating on the stock in a research report on Thursday, February 13th. HSBC lowered Biogen from a "buy" rating to a "hold" rating and set a $118.00 price target on the stock. in a research note on Monday. Finally, Sanford C. Bernstein initiated coverage on Biogen in a report on Tuesday, February 11th. They set a "market perform" rating and a $160.00 price objective for the company. Twenty investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, Biogen currently has an average rating of "Hold" and an average target price of $201.93.

Insiders Place Their Bets

In other news, Director Stephen A. Sherwin sold 8,760 shares of the firm's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $150.02, for a total value of $1,314,175.20. Following the transaction, the director now directly owns 11,318 shares in the company, valued at approximately $1,697,926.36. This trade represents a 43.63 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.